Regulatory FDA issues complete response letter to Replimune’s RP1 for melanoma Pharmaceutical TechnologyThe FDA has issued a complete response letter to Replimune's biologics license application concerning the RP1 therapy.RegulatoryOncologyRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) Pharmaceutical Technology The FDA has issued a complete response letter to Replimune’s biologics license application concerning the RP1 therapy. RegulatoryOncologyRead full story Post navigation Previous: FDA hands another rejection to Replimune’s melanoma therapyNext: Data backs GSK’s ovarian cancer blockbuster hopes Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026